Celcuity (NASDAQ:CELC) Price Target Lowered to $140.00 at Needham & Company LLC

Celcuity (NASDAQ:CELC) had its price target lowered by Needham & Company LLC from $157.00 to $140.00 in a report released on Friday, Marketbeat reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Citizens Jmp increased their price objective on Celcuity from $160.00 to $177.00 and gave the stock a “market outperform” rating in a research report on Wednesday, July 15th. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research note on Thursday, May 28th. Craig Hallum reiterated a “buy” rating and set a $178.00 price target on shares of Celcuity in a report on Wednesday, July 15th. Finally, Wells Fargo & Company cut their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $153.64.

Celcuity Price Performance

CELC stock opened at $92.00 on Friday. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The firm has a market capitalization of $4.49 billion, a PE ratio of -21.40 and a beta of 0.20. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The business has a 50 day simple moving average of $93.88 and a 200-day simple moving average of $108.45.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities research analysts anticipate that Celcuity will post -3.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several hedge funds have recently bought and sold shares of the company. NEA Management Company LLC grew its position in Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after acquiring an additional 1,391,300 shares in the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Celcuity during the fourth quarter worth about $310,302,000. Soleus Capital Management L.P. boosted its stake in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the period. Vanguard Group Inc. grew its holdings in shares of Celcuity by 10.7% in the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after purchasing an additional 220,386 shares in the last quarter. Finally, State Street Corp increased its stake in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after buying an additional 914,887 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.